
How did pharma firms develop COVID-19 vaccine so quickly?
February 18, 2021/by Beth Zalcman
How will the new administration affect non-dilutive funding?
February 7, 2021/by Beth Zalcman
How COVID-19 raised the profile of non-dilutive funding
February 7, 2021/by Beth Zalcman
Inova Immunology Virtual Partnering
January 26, 2021/by Beth Zalcman
Inova Oncology Virtual Partnering
January 26, 2021/by Beth Zalcman
Opening Remarks at NDFS
January 21, 2021/by Beth Zalcman
BARDA at NDFS
January 21, 2021/by Beth Zalcman
NIDDK at NDFS
January 21, 2021/by Beth Zalcman
NIA at NDFS
January 21, 2021/by Beth Zalcman
NHLBI at NDFS
January 21, 2021/by Beth Zalcman
NCATS at NDFS
January 21, 2021/by Beth Zalcman
NIAID at NDFS
January 21, 2021/by Beth ZalcmanSearch
Recent Posts
BIO Partnering for Oncology, May 28-31, 2026, Chicago, USAApril 15, 2026 - 8:22 am
LSX Nordic Congress, May 19-20, 2026, Copenhagen, DenmarkApril 15, 2026 - 8:15 am
AngloNordic, April 23, 2026, LondonMarch 19, 2026 - 12:29 pm
Despite Delays, NIH Grants Deliver Remarkable Economic and Scientific ValueMarch 16, 2026 - 7:05 am
BioTrinity, April 14-15, 2026, LondonMarch 15, 2026 - 11:02 am
